Literature DB >> 17018393

The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.

Karen J Phekoo1, Mike A Richards, Henrik Møller, Steve A Schey.   

Abstract

There is a paucity of epidemiological data on chronic myeloproliferative disorders and myelodysplastic syndromes (MDS), while subtypes of acute myeloid leukemia (AML) are rarely defined. We identified 2,112 adult myeloid malignancies in the South Thames area between 1999 and 2000. The incidence (European standard population) of AML was 3.00/100,000, that of MDS 3.47/100,000, chronic myelomonocytic leukemia (CMML) 0.46/100,000, idiopathic myelofibrosis (IMF) 0.37/100,000, polycythemia vera (PV) 1.08/100,000, primary thrombocythemia (PT) 1.65/100,000 and chronic myeloid leukemia (CML) 1.09/100,000. The 3-year survival for AML was 15%, MDS 45%, CMML 29%, IMF 48%, PV 80%, PT 81% and CML 50% We believe this study reflects the true incidence and outcome of myeloid malignancies in South East England.

Entities:  

Mesh:

Year:  2006        PMID: 17018393

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  33 in total

1.  Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).

Authors:  Marc Maynadié; François Girodon; Ines Manivet-Janoray; Morgane Mounier; Francine Mugneret; François Bailly; Bernardine Favre; Denis Caillot; Tony Petrella; Michel Flesch; Paule-Marie Carli
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 2.  Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.

Authors:  Ros Wade; Micah Rose; Aileen Rae Neilson; Lisa Stirk; Rocio Rodriguez-Lopez; David Bowen; Dawn Craig; Nerys Woolacott
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

3.  Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.

Authors:  François Girodon; Gilles Bonicelli; Céline Schaeffer; Morgane Mounier; Serge Carillo; Ingrid Lafon; Paule Marie Carli; Inès Janoray; Emmanuelle Ferrant; Marc Maynadié
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

4.  Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain.

Authors:  Gemma Osca-Gelis; Montserrat Puig-Vives; Marc Saez; David Gallardo; Natalia Lloveras; Rafael Marcos-Gragera
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 5.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 6.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Authors:  V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann
Journal:  Leukemia       Date:  2015-03-18       Impact factor: 11.528

8.  SMT-A07, a 3-(Indol-2-yl) indazole derivative, induces apoptosis of leukemia cells in vitro.

Authors:  Shijing Qian; Ji Cao; Yan Yan; Maotang Sun; Hong Zhu; Yongzhou Hu; Qiaojun He; Bo Yang
Journal:  Mol Cell Biochem       Date:  2010-08-06       Impact factor: 3.396

Review 9.  Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.

Authors:  Aline Renneville; Mrinal M Patnaik; Onyee Chan; Eric Padron; Eric Solary
Journal:  Leukemia       Date:  2021-06-26       Impact factor: 11.528

10.  The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Randall J Olsen; Cherie H Dunphy; Dennis P O'Malley; Lawrence Rice; April A Ewton; Chung-Che Chang
Journal:  J Hematop       Date:  2008-08-28       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.